Bristol-Myers Squibb will pay Halozyme $105 million for the right to use the smaller company's technology to develop easier-to-use versions of its best-selling cancer immunotherapy Opdivo, as well as as many as 11 other drugs in the larger company's research pipeline.
from Forbes Real Time https://www.forbes.com/sites/matthewherper/2017/09/14/bristol-to-pay-halozyme-105-million-to-make-new-cancer-drugs-easier-to-take/
via IFTTT
No comments:
Post a Comment